TCT-725 Point-of-Care Genetic Testing of Eleven CYP2C19 Single Nucleotide Polymorphisms Identifies Extensive and Reduced Metabolizers of Clopidogrel With High Accuracy in Patients With Coronary Artery Disease
David Erlinge(Lund University), Paul A. Gurbel(Sinai Hospital), Suman Duvvuru(Eli Lilly (United States)), Stefan James(Uppsala University), Patricia Brown(Eli Lilly (United States)), Henrik Wanger(Innovation Skåne (Sweden)), Scott S. Sundseth, Kenneth J. Winters(Eli Lilly (United States)), Christoph Varenhorst, Udaya Tantry(Sinai Hospital), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Joseph R. Walker(Daiichi Sankyo (United States)), David S. Small(Eli Lilly (United States)), Brian A. Moser(Eli Lilly (United States))
Cited by 1
Related Papers
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
|European Heart Journal|2017|3k
Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest
|New England Journal of Medicine|2013|2.8k